Loading…
Adaptive Biotechnologies Corporation is projected to rise to $30.47 by 2027, a +45% move from its current price of $21.06. ADPT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $20.27 | $21.07 | $21.90 | +0.04% |
| Jul 14 | $19.96 | $21.08 | $22.26 | +0.07% |
| Jul 15 | $19.72 | $21.08 | $22.54 | +0.11% |
| Jul 16 | $19.53 | $21.09 | $22.78 | +0.15% |
| Jul 17 | $19.36 | $21.10 | $23.00 | +0.18% |
| Jul 18 | $19.20 | $21.11 | $23.20 | +0.22% |
| Jul 19 | $19.07 | $21.11 | $23.38 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.07 | $21.11 | $23.38 | +0.26% |
| Week 2 | $18.32 | $21.17 | $24.45 | +0.52% |
| Week 3 | $17.79 | $21.22 | $25.33 | +0.78% |
| Week 4 | $17.35 | $21.28 | $26.10 | +1.04% |
| Week 5 | $16.98 | $21.33 | $26.80 | +1.30% |
| Week 6 | $16.66 | $21.39 | $27.46 | +1.56% |
| Week 7 | $16.37 | $21.44 | $28.09 | +1.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Adaptive Biotechnologies Corporation is a healthcare company described as a commercial-stage company that develops an immune medicine platform for the diagnosis and treatment of various diseases. Its immunosequencing platform combines proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It offers the clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD).
The company provides products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies Corporation (ADPT) trades at $20.96 per share and sits in the healthcare sector as a commercial-stage company focused on immune medicine platforms. It has a market capitalization of $3.35B and ranks 1669 in market size.
The price outlook implied by the provided forecasts shows an evolving path through 2026 to 2050. The 2026 average price is $20.96 with a 2026 min of $12.41 and a 2026 max of $31.21 and a 2026 ROIPct of 0, with sentiment Neutral. By 2030 the average is $43.99 and by 2040 the average is $197.42, rising to an average of $348.56 by 2050, with a maximum pathway reaching up to $771.93.
The forecast spans multiple years with bullish sentiment from 2027 onward and ROIPct values climbing from 46 in 2027 to 1563 in 2050, indicating substantial upside under the provided assumptions.
A major floor 41.6% below — a decisive break under it would weaken the trend.
The nearest floor, 28.1% below — buyers have tended to step in here.
The nearest ceiling, 6.2% above — a clean break opens room to run.
A major ceiling 27.0% above — clearing it would confirm fresh momentum.
Key ADPT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADPT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.07 | Sell | $21.11 | Sell |
| MA 10 | $21.27 | Sell | $20.77 | Buy |
| MA 20 | $19.61 | Buy | $19.73 | Buy |
| MA 50 | $16.60 | Buy | $17.66 | Buy |
| MA 100 | $15.52 | Buy | $16.49 | Buy |
| MA 200 | $15.98 | Buy | $15.29 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.67 | Neutral |
| Stoch RSI (14) | 15.52 | Buy |
| CCI (20) | 56.04 | Neutral |
| Williams %R (14) | -25.49 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | 22.23 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 74.51 | Neutral |
| TRIX (15) | 1.26 | Buy |
| Awesome (5,34) | 3.10 | Buy |
| Ultimate (7,14,28) | 54.98 | Neutral |
| Momentum (10) | 0.81 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 20.85 | Buy |
| ADX (14) | 28.87 | Buy |
| ATR (14) | 0.72 | Info |
The 30-day technical picture shows a bullish setup with a current price of $20.96 and a 30-day range from $15.91 to $27.61. The RSI(14) is 70, indicating strong momentum, while the price trades above both the SMA50 ($15.19) and SMA200 ($15.57).
Key near-term levels include a support at $12.71 and a resistance at $20.25. The 30-day range suggests room for movement toward the upper end of the range, with current price slightly above the resistance level, signaling potential for continued upside in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.41 | $21.06 | $30.90 | 0% | Neutral | |
| $23.33 | $30.47 | $42.61 | +45% | Bullish | |
| $26.04 | $35.44 | $52.06 | +68% | Bullish | |
| $26.82 | $37.79 | $57.67 | +79% | Bullish | |
| $30.47 | $44.27 | $69.76 | +110% | Bullish | |
| $37.02 | $55.35 | $89.66 | +163% | Bullish | |
| $48.95 | $75.17 | $124.78 | +257% | Bullish | |
| $55.27 | $87.05 | $147.75 | +313% | Bullish | |
| $57.99 | $93.57 | $162.07 | +344% | Bullish | |
| $65.38 | $108.00 | $190.61 | +413% | Bullish | |
| $108.37 | $199.62 | $380.82 | +848% | Bullish | |
| $163.99 | $364.43 | $777.05 | +16.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.41 | $21.06 | $26.01 | +0.00% |
| August 2026 | $18.65 | $22.26 | $27.45 | +5.68% |
| September 2026 | $18.07 | $21.78 | $27.28 | -2.14% |
| October 2026 | $17.84 | $21.70 | $27.52 | -0.39% |
| November 2026 | $18.75 | $22.97 | $29.46 | +5.88% |
| December 2026 | $19.34 | $23.86 | $30.90 | +3.86% |
Click any year to see its month-by-month ADPT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ADPT price prediction for 2026 points to an average of $21.06 (low $12.41, high $30.90) — a potential gain of 0% on today's $21.06. Price action looks broadly range-bound.
In 2027, ADPT is projected to trade between $23.33 and $42.61, averaging $30.47 — a potential gain of +45% from today's $21.06. That is up +45% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Adaptive Biotechnologies Corporation's 2028 outlook centres on $35.44, within a $26.04 to $52.06 range. That is up +16% on the projected 2027 average. That marks a +68% change versus current levels. Momentum favours further upside here.
By 2029, ADPT could reach as high as $57.67, with a base case around $37.79 and support toward $26.82 — roughly +79% from $21.06. Buyers look set to stay in control over this stretch.
Expect ADPT to range from $30.47 to $69.76 through 2030. The $44.27 average target implies a +110% move from current prices. That is up +17% on the projected 2029 average. Momentum favours further upside here.
The ADPT price prediction for 2031 points to an average of $55.35 (low $37.02, high $89.66) — a potential gain of +163% on today's $21.06. Buyers look set to stay in control over this stretch.
In 2032, ADPT is projected to trade between $48.95 and $124.78, averaging $75.17 — a potential gain of +257% from today's $21.06. That is up +36% on the projected 2031 average. Momentum favours further upside here.
Adaptive Biotechnologies Corporation's 2033 outlook centres on $87.05, within a $55.27 to $147.75 range. That is up +16% on the projected 2032 average. That marks a +313% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ADPT could reach as high as $162.07, with a base case around $93.57 and support toward $57.99 — roughly +344% from $21.06. Momentum favours further upside here.
Expect ADPT to range from $65.38 to $190.61 through 2035. The $108.00 average target implies a +413% move from current prices. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ADPT price prediction for 2040 points to an average of $199.62 (low $108.37, high $380.82) — a potential gain of +848% on today's $21.06. Momentum favours further upside here.
In 2050, ADPT is projected to trade between $163.99 and $777.05, averaging $364.43 — a potential gain of +16.3x from today's $21.06. That is up +83% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADPT today (≈ 47.483381 ADPT) could be worth
$17,304.33
+$16,304.33 (+1630%) by 2050 · US Dollar
Based on the average projected ADPT price of $364.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADPTwould be worth at today's price.
$1,000 invested in ADPT on Jul 10, 2025 (≈ 82.781457 ADPT) would be worth
$1,743.38
+$743.38 (+74.3%) today · 1.74× · US Dollar
Based on a ADPT entry price of $12.08 vs. today's $21.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.19 | $993.87 | -0.6% |
| 1 month ago | $17.07 | $1,233.74 | +23.4% |
| 3 months ago | $12.79 | $1,646.6 | +64.7% |
| 6 months ago | $18.26 | $1,153.34 | +15.3% |
| 1 year ago | $12.08 | $1,743.38 | +74.3% |
| All time (5.0y) ago | $36.73 | $573.37 | -42.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADPT forecast.
Our base-case forecast reaches $42.00 around 2030.
Implied market cap at $42.00: $6.72B
Over the multi-year horizon, the outlook shows meaningful upside. The 2030 average price is $43.99 with an implied ROI of 109.9 and bullish sentiment. The forecast continues to lift the average to $197.42 by 2040 (ROI 841.9) and to $348.56 by 2050 (ROI 1563), with a bullish stance across these years.
In the intermediate years, the 2027 average is $30.60 (ROI 46) and the 2028 average is $35.82 (ROI 70.9), followed by 2029 at $36.12 (ROI 72.3). The progression through 2031, 2032, and 2033 shows continued gains in the average price to $56.17, $72.80, and $87.16 respectively, all with bullish sentiment. These figures illustrate a long-run uptrending path but remain estimates, not guarantees, and are subject to market and company-specific risks.
Tap a question to reveal the answer.
2030: avg $43.99, min $29.56, max $70.93; ROIPct 109.9; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages through 2030, 2040, and 2050 (e.g., avg $43.99 by 2030 and $348.56 by 2050) and ROIs up to 1563. These are estimates and not guarantees.
Yes. The 2035 forecast shows avg $104.03 and max $189.02, and the 2040 max reaches $389.22, indicating the potential to exceed $100 according to the provided projections.
Current price is $20.96 per share and market capitalization is $3.35B.
The 30-day range is $15.91 to $27.61.
Adaptive Biotechnologies Corporation Community Discussion
0Share your Adaptive Biotechnologies Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.